Contrary to these findings, in the same prospective randomized controlled trial, Kollerits et al. revealed that ApoA-IV did not impact upon the atherogenic risk: fatal myocardial infarction (p = 0.11) and nonfatal myocardial infarction (p = 0.14), fatal or nonfatal stroke (p = 0.18), or cardiovascular interventions (p = 0.62) [31]. The gene discussed is APOA4; the disease is myocardial infarction.